Twitter Linkedin Instagram

Publications

Until a relevant regulatory agency has approved a Cara Therapeutics product for a specific disease or population, any scientific publication or presentation regarding such disease or population is not to be considered instructions on the use of the Cara Therapeutics product or clinical development candidate.

If you have any questions about our papers, please contact us.

Pruritus in Dialysis Dependent Chronic Kidney Disease

Efficacy of Difelikefalin for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies
Topf J, et al. Kidney Medicine. 2022;4(8): 100512.
Safety and Tolerability of Difelikefalin for the Treatment of Moderate-to-Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program
Fishbane S, et al. Kidney Medicine. 2022;4(8): 100513.
Reduction of Pruritus by Difelikefalin Correlates with Reductions in Markers for Pruritus and Inflammation in Subjects Undergoing Hemodialysis
Shirazian S, et al. Presented at the National Kidney Foundation Spring Clinical Meetings, 2022.
An Open-label, Multicenter Study to Evaluate the Safety and Effectiveness of Intravenous Difelikefalin in Patients with Moderate-to-Severe Pruritus Undergoing Hemodialysis
Weiner D, et al. Presented at the European Renal Association – European Dialysis and Transplant Association Congress, 2021.
A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus
Fishbane S, et al. New England Journal of Medicine. 2020;382: 222-232
Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients
Fishbane S, et al. Kidney International Reports. 2020;5: 600-610

Pruritus in Non-Dialysis Dependent Chronic Kidney Disease

Efficacy and Safety of Oral Difelikefalin in Chronic Kidney Disease With Moderate-to-Severe Pruritus: A Randomised, Placebo-Controllled, Phase 2 Trial
Yosipovitch G, et al. Presented at the American Academy of Dermatology Annual Meeting, 2020

Pruritus in Atopic Dermatitis

Oral Difelikefalin Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Subject With Moderate-to-Severe Pruritus
Guttman-Yassky E, et al. Presented at the American Academy of Dermatology Annual Meeting, 2022
Oral Difelikefalin Reduces Pruritus in Atopic Dermatitis
Kim B, et al. Presented at the European Academy of Dermatology and Venereology Congress, 2021

Pruritus in Notalgia Paresthetica

A Phase 2 Study of Oral Difelikefalin for Moderate-to-Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)
Kim B, et al. Presented at the European Academy of Dermatology and Venereology Congress, 2022

Kappa Opioid Receptor Agonism with Difelikefalin

Evaluation of the abuse potential of difelikefalin, a selective kappa-opioid receptor agonist, in recreational polydrug users
Shram M, et al. Clinical and Translational Science. 2022;15: 535-547
Effect of difelikefalin, a selective kappa-opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial
Viscusi E, et al. Clinical and Translational Science. 2021;14: 1886-1893

Kappa Opioid Receptor Agonism with Difelikefalin

Understanding the patient experience of living with notalgia paresthetica: A qualitative interview study
Bacci E, et al. Journal of the American Academy of Dermatology International. 2022;8: 94-101
Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus
Vernon M, et al. Journal of Patient-Reported Outcomes. 2021;5: 1-12
Clinically meaningful change in itch intensity scores: An evaluation in patients with chronic kidney disease-associated pruritus
Vernon M, et al. Journal of the American Academy of Dermatology. 2021;84: 1132-1134